The Artificial Intelligence to the Rescue of Cancer Research
A special issue of Cells (ISSN 2073-4409).
Deadline for manuscript submissions: 30 September 2025 | Viewed by 178
Special Issue Editors
Interests: cancer; tumorigenesis; stemness; artificial intelligence; precision medicine
Interests: cancer stem cells; immortalization; therapy resistance; tumor evolution; cellular senescence
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cancer remains one of the main causes of mortality worldwide, despite significant advances in diagnosis and treatment. In recent years, artificial intelligence (AI) has emerged as a revolutionary tool in cancer research, offering innovative approaches to early detection, personalized therapy, and improved patient outcomes. The management of large amounts of data, including medical imaging, genomic profiles, and clinical records, allows AI to enhance our understanding of cancer biology, enable more accurate diagnoses, and optimize treatment strategies. This progress is driven by advances in machine learning and deep learning, among other techniques, which allow researchers to extract complex patterns, integrate biomedical information, and develop precise predictive models.
This Special Issue will explore the latest developments in AI applications for cancer research, including early detection and screening, predictive modeling for treatment responses, personalized medicine approaches, the integration of multi-omics data for comprehensive cancer profiling, AI-driven drug discovery, and ethical considerations regarding the use of AI in oncology.
Dr. Asunción Espinosa-Sánchez
Dr. Amancio Carnero
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer research
- artificial intelligence
- personalized medicine
- multi-omics data integration
- AI-driven drug discovery
- precision medicine
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
